Clinicopathologic features and treatment of postirradiation sarcoma of bone and soft tissue

J Surg Oncol · 2000 · Classic · cited 99 times

Yoshiya Inoue, Frank J. Frassica, Franklin H. Sim, K. Krishnan Unni, Ivy A. Petersen, Richard A. McLeod

Department of Orthopedics, Mayo Clinic and Mayo Foundation, Rochester

Orthopaedic Oncology

SUMMARY — THE REDUCTIONPostirradiation sarcomas require wide surgical margins for good outcomes; peripheral lesions show better prognosis than central lesions requiring aggressive treatment.
Abstract, as published

BACKGROUND AND OBJECTIVES: An analysis of the clinicopathologic features and treatment of patients with postirradiation sarcoma of bone and soft tissue was performed to guide modern evaluation and management. METHODS: A retrospective analysis of 135 sarcomas in 130 patients was performed. RESULTS: The mean age of the 130 patients was 48 years, and there was a female predominance because of irradiation for carcinomas of the breast and uterus. Indication for irradiation was a soft tissue lesion (such as lymphoma or breast cancer) in 58.5% of patients and a bone lesion (such as giant cell tumor or fibrous dysplasia) in 41.5%. The latent period (interval between irradiation and discovery of the sarcoma) ranged from 4-55 years (mean, 17 years). Of the lesions, 74% were stage IIB (high-grade extra-compartmental) and 24% were stage III (metastases). Ninety-four patients received their treatment at our institution. Of the 61 patients with resectable disease, 49 had amputations and 12 had limb salvage procedures. The 5-year cumulative survival rate was 68.2% for patients with peripheral (extremities, including proximal femur and hip) resectable lesions and 27.3% for patients with central (pelvis, head/neck, and ribs) resectable lesions. The local recurrence rate correlated with the surgical margin achieved: intralesional, 73%, marginal, 64%, and wide, 23%. CONCLUSIONS: The prognosis for patients with peripheral resectable postirradiation sarcomas is good if a wide surgical margin can be achieved. This group of patients should be treated aggressively because they have a new cancer.

Featured in the 2026-06-30 issue.

← The role of molecular pathology in soft tissue tumor diagnosi…Separation surgery for metastatic epidural spinal cord compre… →

The Reduction is a free email digest of newly published orthopaedic literature — a handful of new papers in the subspecialties you choose, each summarized like this one. Subscribe free or browse the archive.